Results 171 to 180 of about 5,852 (197)

Drug resistance mechanism of PncA inMycobacterium tuberculosis

Journal of Biomolecular Structure and Dynamics, 2013
Tuberculosis continues to be a global health threat. Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis treatment. The emergence of strains resistant to PZA represents an important public health problem, as both first- and second-line treatment regimens include PZA. It becomes toxic to Mycobacterium tuberculosis when
Vidya, Rajendran, Rao, Sethumadhavan
openaire   +2 more sources

Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis

Tubercle and Lung Disease, 1998
To characterize the correlation of the mutations in the pncA gene encoding pyrazinamidase (PZase) of Mycobacterium tuberculosis to a loss of PZase activity and development of pyrazinamide (PZA) resistance.The association of PZase activity, minimum inhibitory concentrations (MICs), and mutations in the pncA gene of M.
K, Hirano, M, Takahashi, Y, Kazumi, Y, Fukasawa, C, Abe   +4 more
openaire   +2 more sources

The pncA gene mutations of Mycobacterium tuberculosis in multidrug‐resistant tuberculosis

Biotechnology and Applied Biochemistry, 2021
AbstractThe pncA gene encodes pyrazinamidase enzyme which converts drug pyrazinamide to active form pyrazinoic acid, but mutations in this gene can prevent enzyme activity which leads to pyrazinamide resistance. The cross‐sectional study was carried out during 2016–2017 for 12 months.
Nasir Mahmood, Sadia Bhatti, Shahzada Nadeem Abbas, Saman Shahid, Sarah Bushra Nasir   +4 more
openaire   +2 more sources

A Preliminary Report of Parent/Nurse-controlled Analgesia (PNCA) in Infants and Preschoolers

The Clinical Journal of Pain, 2011
infants and young children are often unable to verbalize pain or advocate for themselves which may increase their risk for poor pain assessment and management. Although patient-controlled analgesia (PCA) has been shown to be safe, effective, and superior to intermittent opioid dosing, infants and young children are not able to operate PCA independently.
Michelle L, Czarnecki, Katherine S, Salamon, Kristen E, Jastrowski Mano, Antonella S, Ferrise, Mickel, Sharp, Steven J, Weisman   +5 more
openaire   +2 more sources

Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis

Journal of Medical Microbiology, 2005
Drug-resistant Mycobacterium tuberculosis poses a significant threat to the treatment of tuberculosis (TB). The current susceptibility testing for the first-line TB drug pyrazinamide (PZA) is not only time-consuming but also difficult, due to the requirement for acid pH for drug activity. Predominantly, resistance to PZA in M. tuberculosis is caused by
Steven, Denkin, Dmitriy, Volokhov, Vladimir, Chizhikov, Ying, Zhang   +3 more
openaire   +2 more sources

Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand

Pathology, 2009
To describe the molecular basis of pyrazinamide (PZA) resistance among Mycobacterium tuberculosis in New Zealand, and to compare the pncA gene sequence among isolates with phenotypic (Bactec 960 and Wayne's assay) evidence of PZA resistance.The pncA gene of 26 clinical isolates of M.
Sushil, Pandey, Sandie, Newton, Arlo, Upton, Sally, Roberts, Dragana, Drinković   +4 more
openaire   +2 more sources

Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis

Molecular Diagnosis, 1998
The gene coding for pyrazinamidase (PZase) activity, pncA, in Mycobacterium tuberculosis was recently cloned, and several mutations which correlate with in vitro resistance to pyrazinamide (PZA) have been identified. During the development of a clinical molecular assay for the detection of PZA resistance, two previously unreported mutations in isolates
B SACHAIS, I NACHAMKIN, J MILLS, D LEONARD   +3 more
openaire   +1 more source

Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.

The new microbiologica, 2009
This study was supported by Government Planning Organization (Project No: 2002KI20500). Project a. title is 'Determination of mutation against major anti-tuberculosis drugs in M. tuberculosis bacilli by DNA sequencing analysis in Turkey'. The authors thank Prof. Dr. Ahmet Sani for technical support.
Yuksel, Pelin, Tansel, Ozlem
openaire   +2 more sources

[Studies on pncA gene mutations in M. tuberculosis isolates].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2002
To understand the mutations of pncA gene in M. tuberculosis isolates, and to evaluate their clinical value.Analyzing the pncA genes in 74 M. tuberculosis clinical isolates with PCR-SSCP and PCR-AS. M. tuberculosis strain H37Rv was used as control.32 drug-sensitive isolates all displayed normal pncA SSCP profile.
X, Wu, J, Zhang, M, Zhong
openaire   +1 more source

Study of the structure–activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis

Biochemical Journal, 2001
In an attempt to investigate the molecular basis of pyrazinamide hydrolysis by the PncA protein from Mycobacterium tuberculosis, we determined the pyrazinamidase activity of nine PncA mutants bearing a single amino acid substitution. Among them, three mutants (D8G, K96T and S104R) had virtually no activity (⩽ 0.004unit/mg), five (F13S, T61P, P69L ...
Nadine LEMAITRE, Isabelle CALLEBAUT, Frédéric FRENOIS, Vincent JARLIER, Wladimir SOUGAKOFF   +4 more
openaire   +1 more source